Slide 1: Early and Accurate Diagnosis of Autism and ADHD
(ASX:BB1) Early and Accurate Diagnosis of Autism and ADHD Introducing an AI-powered smartphone platform for neurometric testing April 2026, BlinkLab Ltd Ignite Investment Summit – Hong Kong, Singapore
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be all inclusive or complet
Slide 3: Corporate Snapshot
Corporate Snapshot CAPITAL STRUCTURE - ASX:BB1 Shares on Issue 153.1M Options on Issue 49.7M Performance Rights 4.4M Founders’/ Directors’ percentage 24.1% Market Cap (A$0.75 share price) A$114.9M Cash (31 Dec 2025 Quarterly + R&D + Cap Raise) ~A$22.8M Henk-Jan Boele, Co-founder Anton Uvarov, Co-fou
Slide 4: What is Autism?
What is Autism? “A neurodevelopmental condition that affects how the brain processes sensory information.” Autism can impact: • Social and emotional functioning • Language and communication • Sensory and motor development • Behavior and interests
Slide 5: Autism: The facts and the challenges
Autism: The facts and the challenges Prevalence in children has grown to up to 3% in the US 1-3 Autism prevalence increases globally 4,5 (1) Center for Disease and Control, World Health Organization; (2) Santomauro et al., (2025) The global epidemiology and health burden of the autism spectrum: find
Slide 6: Autism diagnosis still lacks an objective medical test
Autism diagnosis still lacks an objective medical test There is currently no biomarker, such as a blood test or brain scan, used in clinical practice. Diagnosis relies on behavioral assessments based on DSM-5 Over 100 autism questionnaires have been developed since criteria, using questionnaires and
Slide 7: Australia: NDIS payments for autism is over A$9.9B in 2025
Australia: NDIS payments for autism is over A$9.9B in 2025 Autism accounts for 41% of all NDIS participants, making it the most common disability. Data extracted and visualized by BlinkLab, based on information from the National Disability Insurance Scheme (NDIS) - https://dataresearch.ndis.gov.au/r
Slide 8: Consensus: Early diagnosis and intervention helps children
Consensus: Early diagnosis and intervention helps children to develop crucial skills and reduces long-term support needs and costs Ø Early detection and diagnosis is crucial 1-5 The American Academy of Pediatrics recommends that all children must be screened for autism at ages 18 and 24 months. Chil
Slide 9: BlinkLab's AI-enabled Smartphone-based Assessment
BlinkLab’s AI-enabled Smartphone-based Assessment
Slide 10: Our patented solution: Neuroscience on a smartphone
Our patented solution: Neuroscience on a smartphone Minuscule facial reflexes, evoked by our app, Evokes Facial Reflexes generate a digital biomarker for autism. By presenting visual and auditory stimuli during smartphone use. Computer Vision Facial features are tracked on the smartphone and transfe
Slide 11: High-Profile Journal Publication Validates BlinkLab's Technology
High-Profile Journal Publication Validates BlinkLab’s Technology and Provides Support for Future Clinical Adoption ASX Announcement – 5 January 2026 – High-profile journal publication validates BB1 technology Research Article Link: https://onlinelibrary.wiley.com/doi/10.1002/aur.70166?af=R
Slide 12: Beyond blinks: Tracking of vocal responses and hand/head movements
Beyond blinks: Tracking of vocal responses and hand/head movements as objective markers for autism Screen avoidance Head rotations Side eye Pupil range Postural stability Headphone touches Mouth openings Vocalizations Image used with permission ASX Announcement – 5 January 2026 – High-profile journa
Slide 13: Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial
Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial ASX Announcement 22 October 2025 Highlights: Ø Pilot Study Completion: BlinkLab has successfully completed its U.S. Pilot Study of the Dx 1 diagnostic device, involving 485 children. Ø Strong Diagnostic Performance: Across a c
Slide 14: Why not 100% sensitivity and 100% specificity?
Why not 100% sensitivity and 100% specificity? The performance ceiling for BlinkLab Dx1 is 85-90% due to diagnostic ambiguity and autism heterogeneity. Ø Diagnostic Stability 1st Evaluation Re-evaluation Few years later... Autism clinical diagnostic stability is estimated around 80-90% stability. ¹⁻
Slide 15: BlinkLab Outperforms FDA-approved Digital Peers
BlinkLab Outperforms FDA-approved Digital Peers We are leaders in the digital autism diagnostics space Sensitivity 84% 52%* 71% Specificity 85% 19%* 81% Smartphone-based Yes Yes No FDA approval No - 510(k) Yes - De Novo Yes - 510(k) * Calculated over all study completers (Cognoa’s device yielded ind
Slide 16: Study Design and Timeline for 510(k) Regulatory Trial for Dx 1
Study Design and Timeline for 510(k) Regulatory Trial for Dx 1 Prospective, multicenter in US, double-blinded, within-subject comparison study. Enroll children between 2-11 Q4 2024 - CRO assigned years and sign ICF - IRB approval for Pilot Study - First pre-submission meeting with FDA Q1 2025 - Onbo
Slide 17: BlinkLab Commences Pivotal Validation Program for FDA 510(k) Submission
BlinkLab Commences Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled Ten Leading US Autism Centers will Participate in the 510(k) Pivotal Study Study execution led by CRO partner IQVIA-MCRA, building on strong pilot study. 510(k) FDA submission targeted by year-end 202
Slide 18: BlinkLab Dx1 intended use as a diagnostic aid
BlinkLab Dx1 is intended for use as a diagnostic aid for clinicians in the assessment of autism spectrum disorder in pediatric populations. The system is prescribed by a qualified healthcare professional and The clinician is responsible for enables the collection of behavioral and neurometric data v
Slide 19: We are experts in science, AI, tech, and commercialization
We are experts in science, AI, tech, and commercialization Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist at Erasmus MC and
Slide 20: We are backed up by an expert advisory board
We are backed up by an expert advisory board Company Chairman Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and Experienced bio- Professor of Neuroscience Profess
Slide 21: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.
Slide 22: Catalysts and milestones for Dx1 (autism) and Dx2 (ADHD) models
Catalysts and milestones for Dx1 (autism) and Dx2 (ADHD) models News pipeline on updates our regulatory studies on autism and ADHD and new partnerships BlinkLab Dx 1 – Autism Model Calendar Year BlinkLab Dx 2 – ADHD model Calendar Year Submit CE/MDR clearance 3Q 2026 Complete European ADHD Study 2Q
Slide 23: Commercialization Strategy Assuming FDA clearance
Commercialization Strategy Assuming FDA clearance Strategy applies to Dx1 in the US market only. Substantially lower cost than competing tools, enabled by fully automated testing that allows initial use without reimbursement and accelerates adoption. TAM 1 2027 2028 2029 2030 1. Early Adoption by Au
Slide 24: BlinkLab Selected for Morocco's Nationwide Government-Funded Autism Screening Program
BlinkLab Selected for Morocco’s Nationwide Government-Funded Autism Screening Program ü Roll-out in 3,000 centers to test 600,000 children annually. ü Large-scale adoption before proposed FDA clearance. ü Data ownership and intellectual property retained by BlinkLab. ü Regional and Middle East expan
Slide 25: Sensorimotor biomarkers have been widely studied
Sensorimotor biomarkers have been widely studied, but clinical adoption was limited by technical complexity Over 9000 peer-reviewed studies across neuropsychiatric disorders.
Slide 26: BlinkLab platform expansion: New indications and use cases
BlinkLab platform expansion: New indications and use cases are guided by strong scientific foundation (see previous slide) European ADHD Study Australian MAGNET Study ● Collaborator: Mental Care Group ● Collaborator: Monash University ● Goal: Develop BlinkLab Dx 2 - ADHD Model ● Goal: Genotyping and
Slide 27: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and protection of its intel
Slide 28: ASX:BB1
ASX:BB1 For further information please contact: Henk-Jan Boele, MD, PhD Brian Leedman Cofounder and MD/CEO Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 (0) 611 132 247 M: +61 (0) 412 281 780 info@blinklab.org @BlinkLab.App @Blink_Lab BlinkLab Limited (ASX:BB1) @BlinkLab Ltd